PURPOSE: We hypothesized that a reduction in the size of the lymph nodes after neoadjuvant therapy for locally advanced rectal carcinoma would be associated with decreased lymph node metastases and/or a better prognosis. METHODS: Between March 2006 and April 2012, 71 patients with primary rectal cancer received neoadjuvant chemoradiation therapy (CRT). For all lymph nodes 5 mm or larger in size, the major and minor axes were measured on CT scan images, and the product was calculated. The lymph node size was determined before and after CRT. The patients were divided into three groups based on the lymph node size before and after treatment. Group A exhibited a reduction in size of 60% or more, Group B a reduction of less than 60% and Group C had no lymph node enlargement before treatment. RESULTS: The incidence of lymph node metastases on pathological examination was 15% in Group A and 50% in Group B (p = 0.006). The five-year disease-free survival in Group A was 84% compared with 78% in Group B (log rank p = 0.34). The five-year overall survival in Group A was 92% compared with 74% in Group B (log rank p = 0.088). CONCLUSIONS: A reduction in the size of enlarged lymph nodes after neoadjuvant therapy may be a useful prognostic factor for recurrence and survival.
PURPOSE: We hypothesized that a reduction in the size of the lymph nodes after neoadjuvant therapy for locally advanced rectal carcinoma would be associated with decreased lymph node metastases and/or a better prognosis. METHODS: Between March 2006 and April 2012, 71 patients with primary rectal cancer received neoadjuvant chemoradiation therapy (CRT). For all lymph nodes 5 mm or larger in size, the major and minor axes were measured on CT scan images, and the product was calculated. The lymph node size was determined before and after CRT. The patients were divided into three groups based on the lymph node size before and after treatment. Group A exhibited a reduction in size of 60% or more, Group B a reduction of less than 60% and Group C had no lymph node enlargement before treatment. RESULTS: The incidence of lymph node metastases on pathological examination was 15% in Group A and 50% in Group B (p = 0.006). The five-year disease-free survival in Group A was 84% compared with 78% in Group B (log rank p = 0.34). The five-year overall survival in Group A was 92% compared with 74% in Group B (log rank p = 0.088). CONCLUSIONS: A reduction in the size of enlarged lymph nodes after neoadjuvant therapy may be a useful prognostic factor for recurrence and survival.
Authors: Julio García-Aguilar; Enrique Hernandez de Anda; Prayuth Sirivongs; Suk-Hwan Lee; Robert D Madoff; David A Rothenberger Journal: Dis Colon Rectum Date: 2003-03 Impact factor: 4.585
Authors: Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Nam Kyu Kim; Seung Hyuk Baik; Jin Sil Seong; Hoguen Kim; Jae Kyung Roh; Kang Young Lee; Seung Kook Sohn; Chang Hwan Cho Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: T A Rich; J M Skibber; J A Ajani; D J Buchholz; K R Cleary; R A Dubrow; B Levin; P M Lynch; S H Meterissian; L D Roubein Journal: Int J Radiat Oncol Biol Phys Date: 1995-07-15 Impact factor: 7.038
Authors: Isabelle Bedrosian; Miguel A Rodriguez-Bigas; Barry Feig; Kelly K Hunt; Lee Ellis; Steven A Curley; Jean Nicolas Vauthey; Marc Delclos; Christopher Crane; Nora Janjan; John M Skibber Journal: J Gastrointest Surg Date: 2004-01 Impact factor: 3.452
Authors: Patrick Mayr; Georg Aumann; Tina Schaller; Gerhard Schenkirsch; Matthias Anthuber; Bruno Märkl Journal: Langenbecks Arch Surg Date: 2016-02-16 Impact factor: 3.445